News

Researchers developed a cancer vaccine that uses tumor lysate to enhance immune recognition of solid tumors. The vaccine successfully targets melanoma, breast, lung and ovarian cancers in animal models.

Adding engineered human blood vessel-forming cells to islet transplants boosted the survival of the insulin-producing cells and reversed diabetes in a preclinical trial.

New research led by scientists at La Jolla Institute for Immunology reveals the workings of a human antibody called mAb 3A6, which may prove to be an important component of Ebola virus therapeutics.

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis is being tested in human trials in the UK and Europe.

A Dartmouth-led study finds that early exposure to a tiny dose of HSV in mice leads to cognitive decline later in life. The research suggests low-level neonatal infections may cause lasting neurological effects.

A gene therapy could resolve conduction slowing, improving heart function and protecting against arrhythmias.

University of Michigan researchers developed a sponge-like implant that tracks early immune activity in MS-like disease. Using insights from the implant, they designed nanoparticles that halted or reduced symptoms in mice.

The new Elisabeth Bik Science Integrity Fund will provide financial support to advocates of science integrity.

A phase 2 trial shows that olpasiran, an RNA-based therapy, reduces lipoprotein(a) [Lp(a)] levels by more than 95% in cardiovascular patients. Lp(a) is linked to inflammation, plaque buildup and heart disease risk.

Michigan Medicine researchers have developed a SCN1B gene therapy that restores brain function and survival in mice with severe developmental epileptic encephalopathy (DEE). The therapy reduced seizure severity and increased lifespan.